

2017 Emerging Therapies for PBC, NASH, ESLD and HCC Seminar Series

Seattle, Washington – June 10, 2017

Conference Location	Hyatt at Olive 8 1635 8 th Avenue Seattle, WA, 98101	Phone : (206) 695-1234 www.olive8.hyatt.com
----------------------------	--	--

Parking at the Conference	Self-parking is available across the street at the Grand Hyatt Seattle at a special conference rate of \$9.00 for the day. There is also on-street, metered parking on all roads surrounding the Olive 8
----------------------------------	---

Driving Directions	<p>From I-5 North Bound: Exit from the left lane at Seneca Street. Right on Sixth Avenue. Right on Pike Street. Left on Eighth Avenue. Continue forward through Pine Street. The entrance to our downtown Seattle WA hotel is the second driveway on the left.</p> <p>From I-5 South Bound: Take the Union Street Exit. Continue forward onto Union Street. Turn right on Seventh Avenue. Right on Pike Street. Left on Eighth Avenue. Continue forward through Pine Street. The Hyatt at Olive 8 entrance is the second driveway on the left.</p> <p>From I-90 West Bound: Merge onto I-5 North via Exit #2c toward Madison Street/Convention Center/Vancouver, BC. Take Madison Street/Convention Center exit. Follow exit forward onto Seventh Avenue. Right on Madison Street. Left on Eighth Avenue. Continue forward through Pine Street. The entrance to our Seattle WA downtown hotel is the second driveway on the left</p>
---------------------------	---

Seminar Agenda and Syllabus Information	<p>Registration and breakfast begin at 7:30 a.m. in the Steel Room. Please check signage for any last minute room changes.</p> <p>The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the <i>App</i> will be provided to participants in advance of the seminar. WiFi will be available without charge.</p>
--	--

<i>7:30 am</i>	<i>Registration, Continental Breakfast & View Exhibits</i>
8:00am	Welcome and Pre-Test
8:15 am	<p>End Stage Liver Disease: Treatment, Managing Complications and Transplant</p> <ul style="list-style-type: none"> • Treatment of cirrhosis and hepatic encephalopathy • Management of esophageal varices • Treatment of ascites, edema and hepatorenal syndrome • Liver Transplantation, Listing Criteria and MELD Exceptions
9:05 am	<p>Hepatocellular Carcinoma</p> <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Chemotherapies
9:45 am	<p>Hepatocellular Carcinoma: New Locoregional and Systemic Treatment Options</p> <ul style="list-style-type: none"> • Current treatments with Sorafenib • New chemotherapy treatments in development
<i>10:20 am</i>	<i>Break & View Exhibits</i>

10:35 am	Primary Sclerosing Cholangitis (PBS) <ul style="list-style-type: none"> • Epidemiology • Ursodiol and Antibiotic Treatments • Predicting Outcomes and Improving Survival
11:20 am	New Treatments for PBC <ul style="list-style-type: none"> • Causes and Markers of PBC • Treatment Management • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
12:00 pm	Lunch & View Exhibits
12:45 pm	NAFLD, LAL-D and NASH <ul style="list-style-type: none"> • Epidemiology and Demographics • Diagnosis • Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) Causing Adult Fatty Liver • Conventional treatments
1:20 pm	NASH and LAL-D Treatments in Development <ul style="list-style-type: none"> • Life Style Changes • Obeticholic Acid • Elafibranor (GTR505)
2:00pm	Break & View Exhibits
2:10 pm	Case Presentations: <ul style="list-style-type: none"> • HCC • PBC with inadequate response to Ursodiol • NASH Diagnosis and Treatment
2:50 pm	Post-test
3:10 pm	Adjourn

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.2 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-16-878. The Kentucky Board of Nursing approval of an individual nursing education provide does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)[™] organizations accredited by ACCME.

**Your Seminar
Faculty**



KRIS V. KOWDLEY, M.D.

Dr. Kowdley is internationally recognized as a clinician, educator and researcher in the area of liver disease and has presented his research on liver diseases at more than 135 national and international meetings and scientific symposia. He is the author of over 375 articles, book chapters, reviews and commentaries in this area and has been published in the *Annals of Internal Medicine*, *Archives of Surgery*, *Gastroenterology*, *Hepatology*, *American Journal of Physiology*, *New England Journal of Medicine*, and among other professional publications.

Dr. Kowdley has extensive experience in clinical trials in all areas of liver disease, ranging from hepatitis C, cholestatic liver disease, nonalcoholic steatohepatitis and hepatitis B.

He has been a principal investigator in several NIDDK-sponsored clinical trials in primary biliary cirrhosis, primary sclerosing cholangitis and is a member of executive committee of the nonalcoholic steatohepatitis clinical research network (NASH CRN).



ROBERT CARITHERS, M.D.,

Dr. Robert Carithers is a Professor of Medicine at the University of Washington in Seattle, Washington. In 1990 he became the medical director of the liver transplant program at the University of Washington Medical Center in Seattle.

His primary clinical and research interests include the management of patients with cirrhosis, hepatitis B, hepatitis C, alcoholic liver disease, hepatocellular carcinoma, and liver transplantation.

Dr. Carithers is a fellow of the American College of Physicians, American College of Gastroenterology, and the American Association for the Study of Liver Diseases.



ANNE M. CROGHAN, MN, ARNP

Anne Croghan is a Nurse Practitioner working with patients with liver disease at Swedish Medical Center in Seattle, Washington. A native of Washington DC, Anne has practiced in an academic medical center, a specialty group practice and at Veteran's Administration Medical Center.

Her clinical practice has assisted patients in the evaluation and treatment of hepatitis C, hepatitis B, HCV/HIV co-infected, HBV/HIV co-infected, fatty liver disease, pre- and post-liver transplant patients, and patients with hepatocellular carcinoma. She has also worked as an investigator on multiple clinical trials for viral hepatitis.

Ms. Croghan has also published articles in several recognized medical and nursing journals.
